Saw palmetto extract comparable to prostate drug: Euromed's extract was also found to work as well as saw palmetto extract made with hexane.
In a recent study, Euromed's branded CO2 supercritical saw palmetto extract (Prosterol) was found to work in the same way and just as well as the original prescription drug standard for treating enlarged prostate in men (finasteride). It was also found to work just as well as another well-known saw palmetto extract that is made with the harsh solvent hexane. The study was published in Research and Reports in Urology.
In the trial, the inhibitory potency of saw palmetto supercritical CO2 extract (SPSE) was compared to that of finasteride, an approved 5[alpha]-reductase inhibitor, on the basis of the enzymatic conversion of the substrate androstenedione to the 5[alpha]-reduced product 5[alpha]-androstanedione.
Results determined that by concentration-dependent inhibition of 5[alpha]-reductase type II in vitro (half-maximal inhibitory concentration 3.58 [+ or -] 0.05 [micro]g/mL), SPSE demonstrated competitive binding toward the active site of the enzyme. Finasteride, the approved 5[alpha]-reductase inhibitor tested as positive control, led to 63-75% inhibition of 5[alpha]-reductase type II.
Researchers concluded that SPSE effectively inhibits the enzyme that has been linked to benign prostatic hyperplasia (BPH), and the amount of extract required for activity is comparatively low. It can be confirmed from the results of this study that SPSE has bioactivity that promotes prostate health. The bioactivity of SPSE corresponds favorably to that reported for the hexane extract used in a large number of positive BPH clinical trials, as well as to finasteride. The company said future in vitro and clinical trials involving SPEs would be useful for elucidating their comparative differences, as well as appropriate patient selection for their use.
www. euromedusa, com